$MO

Altria Q2 2026 slides: revenue beat, EPS miss trigger 8% decline

Altria Group reported Q2 2026 results on July 30. Revenue rose 14% to $6.11B, above the $5.35B consensus, but adjusted diluted EPS was $1.48, slightly below the $1.50 estimate. Shares fell 8.52% to $68.54. Cigarette volume declines persisted while smoke-free nicotine pouches grew.

Original reporting
Published Jul 30, 2026, 4:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 6:43 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$MO
Bearish
medium confidence
Mentioned
$MO
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$MOBearishMed
01

Why it matters

Traders may focus on whether smoke-free growth can offset cigarette volume erosion and whether margin gains persist, given the market’s negative reaction to a small EPS miss.

02

Market read

A revenue beat did not prevent a sharp selloff because EPS missed and cigarette volume pressures remained central to the earnings narrative.

03

What to watch

The article highlights rapid on! pouch share gains (59.9% of oral tobacco) and planned national expansion of on! PLUS, which may support longer-duration earnings even if cigarettes keep declining.

Relevance 8/10Novelty 6/10Timing: today’s Q2 2026 earnings reaction and slide disclosures

Background

Altria’s Q2 2026 results show a split between strong revenue/pricing and weaker-than-expected EPS, alongside continued cigarette volume declines.

Company-level read

Ticker impact

$MOBearishMedium confidence
Context

Altria reported Q2 2026 revenue of $6.11B (+14% vs forecast) but adjusted EPS $1.48 missed by $0.02, sending shares down 8.52%.

Expected impact

Near-term downside bias as investors reprice durability of earnings growth amid continued volume declines, despite smoke-free progress.

Evidence & confidence

The article ties the 8.52% drop directly to the EPS miss and cigarette volume headwinds, while smoke-free (on! pouches) progress is described but not enough to offset the earnings disappointment.

Market effects

Reinforces that tobacco investors are still prioritizing EPS and volume trends over revenue beats, even as smoke-free mix improves.

Limited, company-specific read-through for US tobacco equities.

Low, largely US-focused earnings and category dynamics.

Counterpoint

The revenue beat and smokeable operating income margin expansion could indicate earnings resilience, with the EPS miss potentially driven by timing items rather than deteriorating fundamentals.

Key entities

  • Altria Group

    Reported Q2 2026 revenue beat and adjusted EPS miss; shares fell 8.52% to $68.54.

  • on! nicotine pouch (on! PLUS)

    Smoke-free growth driver with expanding store distribution and rising oral tobacco category share.

Related articles

$PMMedAI 8/10

As FDA approves new marketing for nicotine pouches, some doctors sound alarms

The U.S. FDA authorized marketing of four new flavored nicotine pouch products from brand “on!” and raised the total recently approved to 30. The FDA also previously cleared ZYN for 20 products with a “Modified Risk Tobacco Product” claim. Philip Morris makes ZYN and Altria makes “on!”. Health groups cite youth use and addiction risks; FDA says MRTP status does not mean risk-free.

$MOMedAI 8/10

FDA authorizes 4 new nicotine pouches from Altria

The FDA authorized marketing of four On Plus nicotine pouch products made by Helix Innovations, a subsidiary of Altria. The FDA said the review was under a September pilot program and that the pouches have lower levels of most harmful and potentially harmful constituents versus other oral and smokeless products. Altria reported first-half 2026 net revenues up 1.6% to $11.5 billion.

$MOMedAI 8/10

Altria (MO) Q2 2026 Earnings Call Transcript

Altria (MO) reported Q2 2026 adjusted diluted EPS of $1.48, up 2.8%, and $2.80 for the first half, up 4.9%. Full-year guidance was narrowed to $5.61 to $5.72. Smokeable OCI was $3.0B, up 2.4%, with Marlboro pricing strength. Capital returns included $3.6B dividends and $335M buybacks in H1.

$MOMedAI 8/10

Altria (MO) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Mac Livingston Chief Executive Officer - Salvatore Mancuso Chief Financial Officer - Heather Newman TAKEAWAYS Adjusted Diluted EPS -- $1.48 for the second quarter, representing a 2.8% increase, and $2.80 for the first half, up 4.9%. Full-Year Guidance -- Narrowed to a range of $5.61 to $5.72, representing a growth rate of 3.5% to 5.5% from the 2025 base of $5.42.

$MOMed

Why Altria Stock Is Sinking Today

Altria (NYSE: MO) shares fell about 9.3% on Thursday after its Q2 report. Adjusted EPS was $1.48, $0.02 below analysts’ average estimate. Revenue after excise taxes rose 1.2% to $5.36 billion, while cigarette unit shipments fell 4.5% year over year. Altria raised full-year adjusted EPS guidance to $5.61-$5.72.